Boston Scientific Corporation $BSX Shares Sold by Jackson Square Capital LLC

Jackson Square Capital LLC lowered its stake in Boston Scientific Corporation (NYSE:BSX) by 87.1% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 7,272 shares of the medical equipment provider’s stock after selling 49,034 shares during the quarter. Jackson Square Capital LLC’s holdings in Boston Scientific were worth $710,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Steph & Co. purchased a new stake in shares of Boston Scientific during the third quarter worth about $25,000. 1248 Management LLC purchased a new position in Boston Scientific in the 1st quarter worth approximately $26,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Sound Income Strategies LLC grew its position in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. Finally, Kilter Group LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at approximately $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 143,095 shares of company stock valued at $14,228,950 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: RBC Capital continues to rate BSX as an “outperform,” reinforcing buy-side support from a major bank and likely helping demand for shares. RBC Capital maintains Boston Scientific (BSX) outperform recommendation
• Positive Sentiment: Royal Bank of Canada analyst commentary suggests upside ahead for BSX, adding another institutional voice expecting price appreciation. This supports the bullish narrative among analysts. Boston Scientific (NYSE:BSX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
• Positive Sentiment: Truist reaffirmed a “buy” rating on BSX, signaling continued analyst confidence even as the firm updated its outlook—this helps underwrite medium-term investor sentiment. Truist Securities maintains Boston Scientific (BSX) buy recommendation
• Positive Sentiment: Zacks highlights BSX’s global expansion push — R&D, AI-driven manufacturing and a focused Emerging Markets effort targeting $1B+ revenue in China for 2025 — a strategic growth catalyst that supports longer-term upside. Boston Scientific’s Global Expansion: What’s Behind the Growth?
• Neutral Sentiment: Options flow is active around BSX; Benzinga’s options-focused piece notes positioning that can amplify intraday moves but doesn’t definitively indicate directional conviction from fundamental investors. Watch open interest and strike concentration for short-term signals. Decoding Boston Scientific’s Options Activity: What’s the Big Picture?
• Neutral Sentiment: Informational pieces recap BSX’s multi-year performance; useful for context but unlikely to move the stock today. These highlight solid historical returns that underpin investor confidence. Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 5 Years
• Neutral Sentiment: Short-term market commentary notes BSX outperformed earlier sessions; useful for momentum traders but not a standalone fundamental driver. Boston Scientific (BSX) Advances While Market Declines
• Negative Sentiment: Truist cut its price target from $130 to $120 — a downward revision that may cap near-term upside and pressures sentiment despite the maintained “buy” rating. That target trim likely explains some of the selling pressure today. BSX price target lowered by Truist

Boston Scientific Stock Down 0.5%

Shares of NYSE BSX opened at $95.61 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The firm has a market cap of $141.74 billion, a price-to-earnings ratio of 51.13, a PEG ratio of 1.94 and a beta of 0.67. The business’s 50 day moving average is $98.64 and its two-hundred day moving average is $101.28. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on BSX. Robert W. Baird lifted their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Canaccord Genuity Group reduced their price target on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a report on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a research report on Friday, October 17th. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Finally, Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $124.85.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.